Medindia LOGIN REGISTER
Medindia

Side effect(s) of Baricitinib


Review the side-effects of Baricitinib as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the instances these side-effects are mild and easily tolerable, however sometimes they can be more severe and can be detrimental.

If the side effects are not tolerable adjusting the dosage or switching to a different medication can help to manage or overcome side effects. If you have any doubts or questions, we recommend seeking advice from your doctor or pharmacist.

  Gastrointestinal:
Nausea, stomach pain, gastritis, ulcer, gastroenteritis or infectious diarrhea, high levels of blood cholesterol, low-density lipoproteins (LDL), and abnormal liver enzymes (AST (SGOT) and ALT (SGPT)) levels

  Respiratory system:
A sore throat, obstruction of the nose, sinusitis, common cold, swelling of the tonsils and pharynx

  Blood:
Low levels of hemoglobin, neutrophils, and lymphocytes, blood clots

  Kidney:
Urinary tract infections such as cystitis and pyelonephritis


  Others:
Viral infections such as herpes simplex or herpes zoster

Other Precautions :

• Patients or caregivers should consult the physician immediately if any signs or symptoms of infection occur during baricitinib therapy who can suspend the treatment until the infection is controlled.

• Never use baricitinib tablets for reasons it is not prescribed for and do not recommend it to another patient who reports with the same symptoms as you.

Drug Name : Baricitinib

Baricitinib generic Baricitinib tablets are prescribed to treat adult patients suffering from moderate to severe rheumatoid arthritis who show loss of response to one or more tumor necrosis factor antagonist treatment schedules. Baricitinib works by blocking the actions of Janus kinase (JAK) which is involved with the activation of signaling of molecules and the proinflammatory mediators which are found to be responsible for causing autoimmune disorders. Baricitinib is recommended for use either alone or in combination with methotrexate or with other disease-modifying antirheumatic drugs (DMARDs). The European medicines agency (EMA) approved baricitinib tablets to use throughout the EU on Feb 13, 2017. It blocks endogenous cannabinoid binding to neuronal CB1 receptors.


Advertisement
Recommended Reading

Home

Consult

e-Book

Articles

News

Calculators

Drugs

Directories

Education